Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs

• Ahmad Ghorab,
• Aref Al-Kali,
• Michelle Elliot,
• Naseema Gangat,
• Hasan Alkhateeb,
• Mithun Shah,
• Yuanhang Liu,
• Cecilia Arana Yi,
• Hemant Murthy,
• Mohamed Kharfan-Dabaja,
• Ayalew Tefferi,
• Mrinal Patnaik,
• Mark Litzow,
• Talha Badar

Affiliations

Ahmad Ghorab

Division of Hematology and Oncology, Mayo Clinic

Aref Al-Kali

Division of Hematology, Mayo Clinic

Michelle Elliot

Division of Hematology, Mayo Clinic

Naseema Gangat

Division of Hematology, Mayo Clinic

Hasan Alkhateeb

Division of Hematology, Mayo Clinic

Mithun Shah

Division of Hematology, Mayo Clinic

Yuanhang Liu

Department of Quantitative Health Sciences, Mayo Clinic

Cecilia Arana Yi

Division of Hematology and Oncology, Mayo Clinic

Hemant Murthy

Division of Hematology and Oncology, Mayo Clinic

Mohamed Kharfan-Dabaja

Division of Hematology and Oncology, Mayo Clinic

Ayalew Tefferi

Division of Hematology, Mayo Clinic

Mrinal Patnaik

Division of Hematology, Mayo Clinic

Mark Litzow

Division of Hematology, Mayo Clinic

Talha Badar

Division of Hematology and Oncology, Mayo Clinic